A
A
Home
Global websites
Local websites
Locations map

Clinical Trials

 

At argenx, we are united in our commitment to improve the lives of patients by translating immunology innovations into transformative medicines.

The path to pioneer innovations and advance the understanding of autoimmune disease is best achieved through co-creation with patients and their supporters, and our patient advocacy partners.

Most important to our mission are the people who choose to participate in our clinical trials.

 

Empasiprubart

Dermatomyositis (DM)

Empacific

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart in Adults With Dermatomyositis.
Program: Empasibrubart IV

Delayed Graft Function (DGF)

VARVARA

Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of ARGX-117 in Improving Allograft Function in Recipients of a Deceased Donor Renal Allograft at Risk for Delayed Graft Function.
Program: Empasiprubart

Multifocal Motor Neuropathy (MMN)

iMMersioN

A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health-Related Quality of Life, and Health Care Resource Utilization in Adult Patients With Multifocal Motor Neuropathy.

More information

ARGX-117

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy
Program: ARGX-117

More information
argenx MMN study website

Efgartigimod

Generalized Myasthenia Gravis (gMG)

ADAPT Jr. SC

Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis.
Program: Efgartigimod

ADAPT Jr.

Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age with Generalized Myasthenia Gravis
Program: Efgartigimod

Thyroid Eye Disease (TED)

UPLIGHTED

Phase 3 Study to Evaluate the Safety and Efficacy of Self-administered efgartigimod SC injection for Adults with Thyroid Eye Disease (TED).
Program: Efgartigimod

Seronegative gMG

Myositis (IMNM, ASyS, DM)

Bullous Pemphigoid (BP)

Post-Trial Access

At argenx, we believe participation in a clinical trial within a controlled setting is the most appropriate way to access investigational products.

argenx recognizes that during a clinical trial, some participants may feel they have benefited from the investigational product, yet they do not have access to the product after their participation in the trial has ended because it is not yet approved or commercially available in their country.

When an individual request is received from a clinical trial investigator to continue to provide an investigational product to a patient outside the trial, that is commonly referred to as post-trial access.